DDW_Benchling & Proscia_Logo_400px-1
In this webinar, hosted by DDW and co-sponsored by Benchling and Proscia, you will learn about the key benefits and latest innovations to be aware of in AI and lab automation.
You will hear from Jeremy Skillington, CEO of Poolbeg Pharma, and Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, as well as sponsor presentations from Helen Liu-Mayo, Product Manager at Benchling, and Nathan Buchbinder, Co-Founder and Chief Strategy Officer at Proscia.   

Jeremy Skillington will speak about how Poolbeg Pharma has yielded significant breakthroughs in its AI-led programmes targeting influenza and RSV using human challenge trial data, while Alex Zhavoronkov will address the topic 'The benefits of AI in drug discovery'.  

In her presentation, Helen Liu-Mayo answers the question: What is the true opportunity with ML and AI in biotech? Hear from Liu-Mayo on how to pick an AI focus, measure progress and impact to date, and lessons learned.    

In his presentation, Nathan Buchbinder will explore the value of an enterprise-wide data strategy and the critical role that it plays in unlocking new insight and accelerating drug discovery with AI. He will walk through the three critical functions that Proscia’s enterprise pathology platform, Concentriq, performs in putting computational solutions into practice.
What you will learn: 
  • What are the benefits of AI in drug discovery? 
  • How can this technology improve time to market, increase cost savings and drive efficiencies? 
  • What are the key objectives to uptake and how can they be overcome? 
  • What are the benefits of remote labs?
An audience Q&A session with the presenters will follow the webinar presentation.
Watch the webinar on-demand now!

Watch the Webinar